Published in Epigenetics on February 27, 2010
The role of deubiquitinating enzymes in chromatin regulation. FEBS Lett (2010) 0.96
miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer (2012) 0.87
Androgen receptor activation by polychlorinated biphenyls: epigenetic effects mediated by the histone demethylase Jarid1b. Epigenetics (2013) 0.81
KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes. Chem Biol (2015) 0.81
Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res (2014) 0.79
Endocrine disrupters: the new players able to affect the epigenome. Front Cell Dev Biol (2015) 0.79
New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer (2011) 0.79
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene (2016) 0.77
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
Bisphenol A Interaction With Brain Development and Functions. Dose Response (2015) 0.76
Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway. BMC Complement Altern Med (2017) 0.76
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel) (2017) 0.75
Discovery of [1,2,3]Triazolo[4,5-d]pyrimidine Derivatives as Novel LSD1 Inhibitors. ACS Med Chem Lett (2017) 0.75
Food components and contaminants as (anti)androgenic molecules. Genes Nutr (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Translating the histone code. Science (2001) 56.77
Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature (1997) 44.55
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Epigenetics in cancer. N Engl J Med (2008) 17.36
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell (2005) 6.00
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell (2005) 5.74
JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell (2006) 5.54
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature (2006) 4.74
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
Mechanisms of androgen-refractory prostate cancer. N Engl J Med (2004) 4.49
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol (2007) 3.89
Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov (2007) 3.46
Mechanisms involved in the regulation of histone lysine demethylases. Curr Opin Cell Biol (2008) 2.81
An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell (2007) 2.75
A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res (2004) 2.71
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res (2006) 2.62
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate (2004) 2.49
The emerging functions of histone demethylases. Curr Opin Genet Dev (2008) 2.47
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A (2007) 2.45
Functional interplay between histone demethylase and deacetylase enzymes. Mol Cell Biol (2006) 2.20
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A (2007) 2.11
Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol (2007) 2.09
Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst (2000) 2.07
Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev (2000) 1.96
Molecular regulation of androgen action in prostate cancer. J Cell Biochem (2006) 1.81
Targeting histone deacetylase in cancer therapy. Med Res Rev (2006) 1.69
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res (2009) 1.68
Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol (2008) 1.52
Nuclear receptor coregulators in cancer biology. Cancer Res (2009) 1.51
Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer (2002) 1.46
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther (2005) 1.24
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A (2009) 1.23
Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res (2007) 1.19
LSD1 demethylates histone and non-histone proteins. Epigenetics (2009) 1.11
Histone demethylases and cancer. Adv Cancer Res (2009) 1.05
Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res (2006) 1.02
Androgen regulation of the androgen receptor coregulators. BMC Cancer (2008) 0.92
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary (2009) 1.48
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One (2013) 1.29
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A (2009) 1.23
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res (2012) 1.13
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics (2011) 0.89
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs (2010) 0.84
Emerging therapies in castrate-resistant prostate cancer. Curr Urol Rep (2010) 0.83
hADA2a and hADA3: new players in beta-catenin signaling. Cancer Biol Ther (2008) 0.75